Cerebral Small Vessel Disease is a progressive cerebrovascular disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
The disease manifests as damage to the brain parenchyma resulting from dysfunction of small cerebral vessels, leading to white matter lesions, lacunar infarcts, microbleeds, and brain atrophy. Increasingly recognized as an active amplifier of neurodegeneration rather than merely a coexisting vascular condition, CSVD operates through intersecting pathways including chronic cerebral hypoperfusion, [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, and [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breakdown (Jin et al., 2025).
Cerebral small vessel disease (CSVD) is an umbrella term encompassing a group of pathological processes that affect the small arteries, arterioles, capillaries, and venules of the brain. It is one of the most common neurological conditions, affecting up to 95% of people over the age of 65 to varying degrees, and is responsible for approximately 25% of ischemic strokes, 45% of dementia cases, and a significant proportion of cognitive decline in aging populations (Pantoni, 2010). CSVD represents a critical link between [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX--, [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, stroke, and age-related cognitive decline.
Cerebral small vessel disease (CSVD) is an umbrella term encompassing a group of pathological processes that affect the small arteries, arterioles, capillaries, and venules of the brain. It is one of the most common neurological conditions, affecting up to 95% of people over the age of 65 to varying degrees, and is responsible for approximately 25% of ischemic stroke [3]s, 45% of dementia [2] lesions, lacunar infarcts, microbleeds, and brain atrophy. Increasingly recognized as an active amplifier of neurodegeneration rather than merely a coexisting vascular condition, CSVD operates through intersecting pathways including chronic cerebral hypoperfusion, oxidative stress, and [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breakdown (Jin et al., 2025)) (Prevalence et al., 2001).
The STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) consortium has established a widely adopted classification system for CSVD. The updated STRIVE-2 criteria recognize six etiological categories (Wardlaw et al., 2013; Duering et al., 2023) (Neuroimaging et al., 2013):
The most common form, associated with aging and [hypertension]. Characterized by fibrinoid necrosis, lipohyalinosis, and arteriosclerotic changes in small penetrating arteries. This form is strongly linked to traditional cardiovascular risk factors (Optimizing et al., 2025).
Caused by deposition of [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- in the walls of cortical and leptomeningeal vessels. Strongly associated with [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and may represent a vascular manifestation of amyloid pathology. CAA preferentially affects posterior brain regions and causes lobar microbleeds and superficial siderosis (Greenberg et al., 2020). See also [Cerebral Amyloid Angiopathy[/diseases/[cerebral-amyloid-angiopathy[/diseases/[cerebral-amyloid-angiopathy[/diseases/[cerebral-amyloid-angiopathy--TEMP--/diseases)--FIX-- (Cerebral et al., 2020.
Includes monogenic forms such as [CADASIL[/diseases/[cadasil[/diseases/[cadasil[/diseases/[cadasil--TEMP--/diseases)--FIX-- (NOTCH3 mutations), CARASIL (HTRA1 mutations), [Fabry disease[/diseases/[fabry-disease[/diseases/[fabry-disease[/diseases/[fabry-disease--TEMP--/diseases)--FIX--, and COL4A1/COL4A2-related small vessel disease. These forms are less common but provide critical insights into disease mechanisms ([Small et al., 2019](https://doi.org/10.1038/s41582-019-0214-0.
Inflammatory and immune-mediated small vessel diseases encompass both primary and secondary CNS vasculitides. Primary angiitis of the CNS (PACNS) presents with headache, cognitive decline, and multifocal neurological deficits; diagnosis requires brain biopsy showing transmural inflammation of small vessels. Secondary vasculitis may result from systemic autoimmune conditions including systemic lupus erythematosus, Behçet disease, Sjögren syndrome, and sarcoidosis. neuroinflammation contributes directly to vessel wall damage through immune cell infiltration, complement activation, and cytokine-mediated endothelial injury. Unlike arteriosclerotic CSVD, inflammatory forms can affect patients at any age and may respond to immunosuppressive therapy.
Periventricular venous collagenosis involves progressive thickening of venular walls with collagen deposition, leading to luminal narrowing and impaired venous drainage. This process is increasingly recognized as a major contributor to periventricular white matter hyperintensities (WMH) in the elderly, particularly in the deep periventricular regions where single draining veins serve large territories of white matter. Venous collagenosis may impair the [glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX-- by disrupting perivascular drainage pathways. Histopathological studies show that venular collagenosis is found in >65% of individuals over age 60, correlating with WMH severity and cognitive decline.
Encompasses several less common etiologies of small vessel pathology:
MRI is the primary tool for detecting and quantifying CSVD burden in vivo. The STRIVE (STandards for ReportIng Vascular changes on nEuroimaging) criteria provide a standardized framework for identifying and reporting CSVD neuroimaging markers (Wardlaw et al., 2013). Total CSVD burden scores, combining multiple markers (WMH, lacunes, CMBs, EPVS), have been developed to capture the overall impact of small vessel pathology and predict clinical outcomes more accurately than any single marker alone:
Bright signal on T2-weighted and FLAIR MRI sequences, reflecting demyelination, gliosis, and axonal loss in white matter. WMH are the most common and earliest marker of CSVD, graded using the Fazekas scale. They are associated with cognitive decline, increased stroke risk, and progression to dementia (Debette & Markus, 2010).
Small subcortical infarcts (3-15 mm) resulting from occlusion of a single penetrating artery. Acute lacunar infarcts appear as hyperintensities on diffusion-weighted imaging. Chronic lacunes are fluid-filled cavities that represent healed infarcts. They are located in deep gray matter, white matter, and brainstem.
Small, rounded, hypointense foci (typically 2–10 mm) on T2*-weighted gradient echo or susceptibility-weighted imaging (SWI), representing hemosiderin deposits from prior microhemorrhages. Their distribution pattern has important diagnostic and prognostic value:
CMB count correlates with overall CSVD severity and is associated with cognitive impairment, increased risk of both ischemic and hemorrhagic stroke, and future dementia. The presence of >5 CMBs significantly increases the risk of anticoagulation-associated intracerebral hemorrhage, influencing treatment decisions in patients with atrial fibrillation.
Fluid-filled spaces surrounding perforating vessels, visible on T2-weighted MRI. Centrum semiovale EPVS are associated with CAA, while basal ganglia EPVS are associated with hypertensive arteriopathy. EPVS may reflect impaired [glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX-- drainage.
Generalized or focal brain volume loss that occurs as a downstream consequence of CSVD. CSVD-related atrophy affects both gray and white matter:
Brain atrophy rate correlates strongly with WMH progression and total CSVD burden. Importantly, the rate of atrophy mediates the relationship between CSVD markers and cognitive decline, suggesting it reflects cumulative neuronal damage. Brain atrophy is now considered both a marker and consequence of CSVD, and is being used as an outcome measure in clinical trials of CSVD interventions.
Tiny ischemic lesions (typically <1 mm) in the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, often below the detection threshold of conventional 1.5T or 3T MRI but identifiable on ultra-high-field (7T) MRI and at autopsy. Their significance is increasingly recognized:
WMH are present in >90% of individuals over 65 years (de Leeuw et al., 2001)
Lacunar infarcts are found in approximately 20-28% of elderly populations
Cerebral microbleeds are present in 15-25% of older adults
Enlarged perivascular spaces are seen in 40-50% of adults over 60
CSVD prevalence increases sharply with age. Population-based MRI studies show that:
WMH are present in >90% of individuals over 65 years (de Leeuw et al., 2001)
Lacunar infarcts are found in approximately 20-28% of elderly populations
Cerebral microbleeds are present in 15-25% of older adults
Enlarged perivascular spaces are seen in 40-50% of adults over 60
CSVD accounts for approximately 25% of ischemic strokes and is the most common cause of [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX--. It contributes to up to 45% of all dementia cases worldwide, either as the primary cause or as a co-pathology amplifying [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (Gorelick et al., 2011).
The central initiating event in CSVD is endothelial dysfunction, leading to impaired cerebrovascular reactivity, reduced nitric oxide bioavailability, and increased Blood-Brain Barrier permeability. Endothelial cells line the cerebral microvasculature and regulate blood flow, immune cell trafficking, and nutrient transport ([Wardlaw et al., 2019](https://doi.org/10.1038/s41582-019-0212-2.
[BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- disruption allows plasma proteins (including fibrinogen, albumin, and immunoglobulins) to leak into perivascular spaces and brain parenchyma, triggering neuroinflammation and direct tissue damage. Dynamic contrast-enhanced MRI studies demonstrate that [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- leakage is increased in CSVD patients even in normal-appearing white matter.
Structural changes in small vessels reduce cerebral blood flow, particularly in deep white matter regions supplied by long penetrating arteries with limited collateral circulation. Chronic hypoperfusion leads to:
Several monogenic CSVD syndromes have been identified:
Genome-wide association studies (GWAS) have identified over 50 independent genetic loci associated with CSVD markers. Key findings include (Sargurupremraj et al., 2020)):
CSVD typically presents with:
Intensive blood pressure control is the most evidence-based intervention. The SPRINT-MIND trial demonstrated that targeting systolic blood pressure <120 mmHg reduced white matter lesion progression compared to standard treatment (<140 mmHg) (Nasrallah et al., 2019). Calcium channel blockers show particular genetic evidence for benefit in CSVD.
Single antiplatelet therapy (aspirin or clopidogrel) is used for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy is generally avoided due to increased hemorrhage risk, particularly in patients with CAA.
Statins are commonly used in CSVD management, though their benefit extends beyond simple cholesterol reduction:
Non-pharmacological interventions are foundational to CSVD management and prevention:
CSVD and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- frequently co-occur and interact synergistically. Vascular pathology:
Several ongoing trials are investigating:
The study of Cerebral Small Vessel Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- is both a cause and consequence of CSVD. Activated [microglia/[NLRP3) that further damage vessel walls and white matter. Systemic inflammation from metabolic syndrome also contributes to vessel pathology.
CSVD disrupts perivascular drainage pathways (the [glymphatic system), leading to accumulation of metabolic waste products including [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau] protein]. This may explain the frequent co-occurrence of CSVD and Alzheimer's pathology (Iliff et al., 2012).
CSVD shares genetic risk factors with [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, particularly through [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX-- and [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX---related pathways. Mendelian randomization studies suggest that genetically determined WMH burden increases risk of both ischemic stroke and intracerebral hemorrhage ([Persyn et al., 2025)(https://academic.oup.com/brain/article/148/6/1936/7921487)).
The relationship between cerebral small vessel disease (CSVD) burden and cognitive decline in dementia remains an area of active investigation. Several key questions separate correlation from causation:
Confounding Factors: Advanced age, hypertension, and cardiovascular risk factors are associated with both increased CSVD burden and cognitive decline. It remains difficult to determine the independent contribution of CSVD to neurodegeneration when these confounders are present.
Biomarker Mediation Hypotheses: Neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and other blood-based biomarkers show promise for monitoring CSVD progression. However, whether these biomarkers mediate the causal pathway from vascular injury to cognitive decline or merely reflect concomitant pathologies remains unclear.
Mixed Pathology Challenge: In clinical populations, most patients exhibit mixed Alzheimer vascular pathology. The relative contribution of CSVD to cognitive impairment in the presence of amyloid and [tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- pathology is difficult to isolate. Autopsy studies suggest additive or synergistic effects, but interventional evidence is limited.
Trial Design Implications: If CSVD contributes causally to dementia, treatments targeting vascular risk factors or CSVD-specific mechanisms should slow cognitive decline. However, recent trials of intensive blood pressure control and other vascular interventions have shown mixed results, raising questions about the timing and magnitude of any causal effect.
Neuroimaging Limitations: Current MRI markers (white matter hyperintensities, lacunes, microbleeds) capture only a fraction of CSVD-related tissue injury. More sensitive biomarkers may reveal causal relationships that are obscured by insensitive imaging endpoints.
Resolving these questions requires longitudinal studies with detailed biomarker characterization, Mendelian randomization approaches to assess causality, and clinical trials specifically targeting CSVD mechanisms.